Diethylstilboestrol for the treatment of prostate cancer: past, present and future

@article{Turo2014DiethylstilboestrolFT,
  title={Diethylstilboestrol for the treatment of prostate cancer: past, present and future},
  author={Rafal Turo and Michal Smolski and Rachel Esler and Magdalena Kujawa and Stephen J. Bromage and Neil Oakley and Adebanji Adeyoju and Stephen C.W. Brown and Richard J. Brough and A. Macgregor Sinclair and Gerald N. Collins},
  journal={Scandinavian Journal of Urology},
  year={2014},
  volume={48},
  pages={14 - 4}
}
Abstract The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen… 
RE: STATE-OF-THE-ART TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER - FORWARD TO THE PAST - AGAIN
TLDR
It is disappointing, if unsurprising, that the long-established and still-evolving contemporary literature demonstrating a role for oestrogen as effective and possibly safer therapy in men with CRPC received no mention in this review.
The resurgence of estrogens in the treatment of castration-resistant prostate cancer
TLDR
The published data on the use of estrogens in CRPC is reviewed to affect its revival as an efficacious treatment option having minimal side effects, with modified dosage and route of administration.
Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica
TLDR
Conjugated oestrogen produced a PSA decline in Jamaican CRPC patients of this study and may therefore be a useful option for secondary therapy of CRPC.
Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?
TLDR
Parenteraloestrogen as single-agent therapy offers potential ben-efits over either oral diethylstilboestrol or LHRHathrough treating the cancer, by suppressing testos-terone to castrate levels, reducing the risk of Cardiovascular hazards of oral oestrogen, and potentially diminishing the oestrogendepletion-relatedtoxicity of LHRHa.
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
TLDR
Second-line agents, traditionally reserved for CRPC, are being studied in metastatic castrate-sensitive prostate cancer, and may offer practice-changing evidence supporting their use.
Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
TLDR
Preliminary results indicate that parenteral oestrogen can mitigate associated osteoporotic risk and that CT scans could provide a more accurate indicator of overall bone quality and hence fracture risk.
Estrogens and prostate cancer
TLDR
A critical literature review of the current basic science and clinical evidence for the interaction between estrogens and CaP shows that estrogens represent a under-recognized contributor in CaP development and progression.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
TLDR
Toremifene with conventional ADT significantly improved the BCR rate in treatment-naïve bone metastatic PC and changes of scores of the visual analogue scale (VAS) and the functional assessment of cancer therapy (FACT).
...
1
2
3
...

References

SHOWING 1-10 OF 102 REFERENCES
Hormonal therapy for prostate cancer: past, present and future
TLDR
Novel hormonal therapy schedules involving intermittent treatment and peripheral androgen blockade are currently in clinical trials, and the mechanism of hormone refractoriness in prostate cancer is an active area of basic science and translational research.
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
TLDR
Diethylstilbestrol is a synthetic ethynil estrogen often used in CRPC as salvage therapy after several hormone manipulations and appears as a reasonable option worth considering in this setting, adding to the compelling data indicating that CRPC is hormone sensitive in a significant proportion of cases, even when pretreated with docetaxel-based chemotherapy.
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
TLDR
Understanding the practical and often subtle issues of docetaxel initiation, duration of therapy, cessation of therapy and treatment holidays is critical for the informed use of this US Food and Drug Administration-approved regimen in men with castration-resistant metastatic prostate cancer.
Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view.
  • M. Bishop
  • Medicine
    British journal of urology
  • 1996
TLDR
Low-dose oestrogen therapy (1 mg/day of DES) is cheap, effective and caused few side-effects, none of which was life-threatening.
The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
TLDR
It is readily apparent from the literature that androgen deprivation with DES can achieve effective prostate cancer control with demonstrable benefits compared to conventional LH-RH agonist therapy.
Carcinoma of the prostate. Hormonal therapy
A selective review of the literature regarding hormonal therapy for patients with carcinoma of the prostate is presented to assess the current status of the following: (1) therapeutic advantages,
Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen
The present pilot study tested the clinical performance of a new pharmacokinetically guided dosing regimen of parenteral estrogen in patients with advanced prostatic carcinoma. The aim was to
Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
TLDR
It is suggested that stilboestrol should no longer be used for prostate cancer when equally effective alternative treatments are available.
...
1
2
3
4
5
...